Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.

$TGTX makes a lot of sense to do a 300M offering here imo

What stuck out was the combined value proposition: efficacy, safety, convenience, marketability, pricing, etc.

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

$TGTX FDA approval for Billion dollar MS drug — great things in store 2023 $DRMA just officially dropped offering, makes me feel company has something good up it’s sleeve.

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

Amazing positive news from the TGTX 20221229 conference call, FDA approved, 🚨🔥🚨 Ublituximab Briumvi: 1) No need for additional funds, no offering, no need for capital raise, because 220 million in cash reserves expected to last until mid 2024.

$IVDA 🧨 No risk of offering, and looks like its heading over $1.00🧨

👇 breakthrough technology, infancy pricing.

It will help the buyout pricing room go fking do it!! !

Based on some buyout pricing model and Kroger offer, $3 or $4 is not unreasonable!!!